<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd has submitted its yearly disclosure to BSE under SEBI's circular on fund raising by large entities via debt securities. The company confirmed that as of March 31, 2025, it does not qualify as a 'Large Corporate' because its outstanding long-term borrowings with original maturity exceeding one year are below the Rs. 1,000 crore threshold. This is a routine annual compliance filing, not a fundraising announcement. The disclosure is signed by Director Vimal Dhirendra Shah (DIN: 01506655) from Ankleshwar.
No material impact on shareholders or stock price — this is a standard regulatory disclosure confirming the company is too small (in terms of long-term debt) to be classified as a Large Corporate. It does not signal any new borrowing, fundraising, or change in the company's debt structure.